ACE and coronary artery disorder: We also found that participants in the pre-stable and post-increase group had lower levels of uric acid, a lower proportion of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) takers, and a lower prevalence of coronary heart disease at baseline as compared to those in the low stable group.